Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

More than two years in­to the Covid-19 pan­dem­ic, we’re not done see­ing its dis­rup­tion of biotech.

That’s ac­cord­ing to Cal­adrius ex­ecs, who cit­ed the pan­dem­ic as one rea­son for sus­pend­ing its Phase IIb tri­al of a cell ther­a­py as a treat­ment for coro­nary mi­crovas­cu­lar dys­func­tion (CMD). The com­pa­ny plans to go ahead on an in­ter­im analy­sis be­fore de­cid­ing what to do with the pro­gram, which was built on a li­cens­ing deal with Shire in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER